ProcartaPlex™ Human Cytokine/Chemokine/Growth Factor Panel 1, 45plex
Invitrogen™

ProcartaPlex™ Human Cytokine/Chemokine/Growth Factor Panel 1, 45plex

The ProcartaPlex Human Cytokine/Chemokine/Growth Factor Panel 1 45plex enables the exploration of immune function by analyzing 45 protein targets inRead more
Have Questions?
Catalog NumberQuantity
EPX450-12171-90196 Tests
Catalog number EPX450-12171-901
Price (CNY)
-
Quantity:
96 Tests

The ProcartaPlex Human Cytokine/Chemokine/Growth Factor Panel 1 45plex enables the exploration of immune function by analyzing 45 protein targets in a single well using Luminex xMAP technology. The panel is comprised of five modular sub-panels that allow for an initial broad screen to determine targets of interest and subsequent studies analyzing specific functional subsets of cytokines that can be purchased separately. The sub-panels are fully combinable with each other or with individual simplex assays corresponding to the targets in the panel. The same targets can be found in the Human Cytokine/Chemokine/Growth Factor Convenience Panel 1 45plex (Cat. No. EPXR450-12171-901) that is in a ready-to-use format that requires less pipetting.

ProcartaPlex preconfigured panels are extensively tested for analyte combinability, interference, and cross-reactivity to provide the highest level of validation and precision. All ProcartaPlex panels are supplied with the necessary reagents to perform the assay.

ProcartaPlex multiplex panels are available in multiple formats across six species (human, mouse, rat, nonhuman primate, porcine, and canine). Visit our ProcartaPlex Immunoassays page for more information and available products.

Target list [bead region]:
Th1/Th2: GM-CSF [44], IFN gamma [43], IL-1 beta [18], IL-2 [19], IL-4 [20], IL-5 [21], IL-6 [25], IL-8 [27], IL-12p70 [34], IL-13 [35], IL-18 [66], TNF alpha [45]

Th9/Th17/Th22/Treg: IL-9 [52], IL-10 [28], IL-17A (CTLA-8) [36], IL-21 [72], IL-22 [76], IL-23 [63], IL-27 [14]

Inflammatory cytokines: IFN alpha [48], IL-1 alpha [62], IL-1RA [38], IL-7 [26], IL-15 [65], IL-31 [37], LIF [15], TNF beta [54]

Chemokines. Eotaxin (CCL11) [33], GRO alpha (CXCL1) [61], IP-10 (CXCL10) [22], MCP-1 (CCL2) [51], MIP-1 alpha (CCL3) [12], MIP-1 beta (CCL4) [47], RANTES (CCL5) [42], SDF-1 alpha [13]

Growth factors: BDNF [57], EGF [56], FGF-2 [75], HGF [46], NGF beta [55], PDGF-BB [77], PlGF-1 [29], SCF [39], VEGF-A [78], VEGF-D [53]

About ProcartaPlex assays for the Luminex platform
ProcartaPlex immunoassays are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously using a Luminex instrument. ProcartaPlex multiplex assays require as little as 25 μL of plasma or serum, or 50 μL of cell culture supernatant, and just four hours to obtain analyzed results.

Features include:
• Reproducible, reliable results—validated as a panel to the highest industry standard, including protein target combinability and cross-reactivity testing
• More results per sample—measure multiple protein targets simultaneously in a single 25–50 μL sample
• Well-established Luminex technology highly referenced multiplexing platform for protein detection and quantitation

ProcartaPlex assays utilize Luminex xMAP (multianalyte profiling) technology for the simultaneous detection and quantitation of up to 80 protein targets in a single 25–50 μL sample—from plasma, serum, cell culture supernatants, and other bodily fluids.

The Luminex beads in the ProcartaPlex assay are internally dyed with precise proportions of red and infrared fluorophores to create spectrally unique signatures that can be identified by the Luminex xMAP detection systems (e.g., Luminex 200, FLEXMAP 3D, and MAGPIX). Similar to a sandwich ELISA, the ProcartaPlex assay uses matched antibody pairs to identify the protein of interest. In a multiplexed assay, each spectrally unique bead is labeled with antibodies specific for a single target protein, and bound proteins are identified with biotinylated antibodies and streptavidin–R-phycoerythrin (RPE). The conjugation of protein-specific antibodies to a distinct bead allows for analysis of multiple targets in a single well.

The most significant difference between a ProcartaPlex assay and ELISA is that the capture antibody in the ProcartaPlex assay is conjugated to a bead and not adsorbed to the microplate well, so the ProcartaPlex assay reagents are free-floating in the solution. For detection, the Luminex 200 instrument, for example, contains two lasers, one to distinguish the spectral signature of each bead and the second to quantify the amount of RPE fluorescence, which is proportional to the amount of protein present in the sample. ProcartaPlex multiplex assays can profile more target proteins using significantly less sample in the same time that it takes to perform a traditional sandwich ELISA.

ProcartaPlex multiplex panels are available in multiple formats across six species (human, mouse, rat, nonhuman primate, porcine, and canine). Visit thermofisher.cn/procartaplex for more information and available products.

For Research Use Only. Not for use in diagnostic procedures.
Specifications
Assay RangeSee Certificate of Analysis
Assay SensitivitySee Certificate of Analysis
For Use With (Equipment)Luminex™ Instruments
FormatMultiplex Kit
Product LineProcartaPlex
Sample TypeSerum, Plasma, Cell Culture Supernatants
Sample VolumeSerum, Plasma: 25 μL; CCS: 50 μL
Shipping ConditionWet Ice
CombinabilityCombinable
Product TypeMultiplex Panel
Quantity96 Tests
Research AreaImmunology, Cytokines, Chemokines, Growth Factors
SpeciesHuman
Unit SizeEach
Contents & Storage

• 2 vials Human Standard Mix A (lyophilized)
• 2 vials Human Standard Mix B (lyophilized)
• 2 vials Human Standard Mix C (lyophilized)
• 1 vial Capture Bead Mix B (1X)
• 1 vial Capture Bead Mix C (1X)
• 1 vial Capture Bead Mix D (1X)
• 1 vial Capture Bead Mix F (1X)
• 1 vial Capture Bead Mix G (1X)
• 1 vial Biotinylated Detection Antibody Mix B (50X)
• 1 vial Biotinylated Detection Antibody Mix C (50X)
• 1 vial Biotinylated Detection Antibody Mix D (50X)
• 1 vial Biotinylated Detection Antibody Mix F (50X)
• 1 vial Biotinylated Detection Antibody Mix G (50X)
• 1 bottle Reading Buffer (1X)
• 1 bottle Wash Buffer (10X)
• 1 bottle Streptavidin-PE (1X)

Citations & References (25)

Citations & References
Abstract
Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection.
Authors:Tay MZ, Rouers A, Fong SW, Goh YS, Chan YH, Chang ZW, Xu W, Tan CW, Chia WN, Torres-Ruesta A, Amrun SN, Huang Y, Hor PX, Loh CY, Yeo NK, Wang B, Ngoh EZX, Salleh SNM, Chavatte JM, Lim AJ, Maurer-Stroh S, Wang LF, Lin RVTP, Wang CI, Tan SY, Young BE, Leo YS, Lye DC, Renia L, Ng LF
Journal:EMBO Mol Med
PubMed ID:34994081
The SARS-CoV-2 Delta (B.1.617.2) variant is capable of infecting vaccinated persons. An open question remains as to whether deficiencies in specific vaccine-elicited immune responses result in susceptibility to vaccine breakthrough infection. We investigated 55 vaccine breakthrough infection cases (mostly Delta) in Singapore, comparing them against 86 vaccinated close contacts who ... More
Effects of altered salt intake and diet on cytokines in humans: A 20-week randomized cross-over intervention study.
Authors:Niiranen T,Erlund I,Jalkanen S,Jula A,Salmi M
Journal:European journal of immunology
PubMed ID:36330564
Zika Virus Infection Preferentially Counterbalances Human Peripheral Monocyte and/or NK Cell Activity.
Authors:Lum FM, Lee D, Chua TK, Tan JJL, Lee CYP, Liu X, Fang Y, Lee B, Yee WX, Rickett NY, Chia PY, Lim V, Leo YS, Matthews DA, Hiscox JA, Ng LFP
Journal:
PubMed ID:29600283
'Zika virus (ZIKV) has reemerged in the population and caused unprecedented global outbreaks. Here, the transcriptomic consequences of ZIKV infection were studied systematically first in human peripheral blood CD14' ... More
Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways.
Authors:Jegaskanda S, Vanderven HA, Tan HX, Alcantara S, Wragg KM, Parsons MS, Chung AW, Juno JA, Kent SJ
Journal:J Virol
PubMed ID:30541850
'Natural killer (NK) cells are an important component in the control of influenza virus infection, acting to both clear virus-infected cells and release antiviral cytokines. Engagement of CD16 on NK cells by antibody-coated influenza virus-infected cells results in antibody-dependent cellular cytotoxicity (ADCC). Increasing the potency of antibody-mediated NK cell activity ... More
Deciphering the state of immune silence in fatal COVID-19 patients.
Authors:Bost P, De Sanctis F, Canè S, Ugel S, Donadello K, Castellucci M, Eyal D, Fiore A, Anselmi C, Barouni RM, Trovato R, Caligola S, Lamolinara A, Iezzi M, Facciotti F, Mazzariol A, Gibellini D, De Nardo P, Tacconelli E, Gottin L, Polati E, Schwikowski B, Amit I, Bronte V
Journal:Nat Commun
PubMed ID:33674591
'Since the beginning of the SARS-CoV-2 pandemic, COVID-19 appeared as a unique disease with unconventional tissue and systemic immune features. Here we show a COVID-19 immune signature associated with severity by integrating single-cell RNA-seq analysis from blood samples and broncho-alveolar lavage fluids with clinical, immunological and functional ex vivo data. This ... More